TRIPP v. ASCENTAGE PHARMA GROUP INTERNATIONAL

CourtDistrict Court, D. New Jersey
DecidedAugust 23, 2023
Docket2:22-cv-05934
StatusUnknown

This text of TRIPP v. ASCENTAGE PHARMA GROUP INTERNATIONAL (TRIPP v. ASCENTAGE PHARMA GROUP INTERNATIONAL) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
TRIPP v. ASCENTAGE PHARMA GROUP INTERNATIONAL, (D.N.J. 2023).

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY

JAMES TRIPP, Plaintiff, v. Civ. No. 22-5934 (KM) (JBC) ASCENTAGE PHARMA GROUP OPINION INTERNATIONAL, ASCENTAGE PHARMA GROUP, INC., and DAJUN YANG, Defendants.

KEVIN MCNULTY, U.S.D.J.: This matter comes before the Court on the motion (DE 4)1 of defendants Ascentage Pharma Group Inc. (“Ascentage”) and Dajun Yang to dismiss the complaint for lack of personal jurisdiction pursuant to Federal Rule of Civil Procedure 12(b)(2) or, alternatively, to transfer the case to the United States District Court for the District of Maryland. For the reasons set forth below, the motion of Ascentage and Yang is GRANTED. I. BACKGROUND James Tripp is a resident of New Jersey and a former employee of Ascentage. (Compl. ¶ 5.) Ascentage is “a biopharmaceutical company that

1 Certain citations to the record are abbreviated as follows: DE = docket entry Compl. = Complaint (DE 1) Def. Br. = Ascentage and Dajun Yang’s Motion to Dismiss (DE 4) Yang Decl. = Declaration of Dajun Yang (DE 4-2 Ex. 1) Cheng Decl. = Declaration of Lily Cheng (DE 4-2 Ex. 2) Pl. Br. = James Tripp’s Opposition to the Motion to Dismiss (DE 5) Tripp Decl. = Declaration of James Tripp (DE 5-1) develops, among other things, therapies for cancers, chronic hepatitis B, and age-related diseases.” (Cheng Decl. ¶ 4.) Ascentage is incorporated in Delaware and has its principal place of business in Maryland. (Compl. ¶ 6; Cheng Decl. ¶ 5.) Dajun Yang is the founder, president, and chief executive officer of Ascentage. (Yang Decl. ¶ 2.) Yang primarily resides in China and has his principal United States residence in Maryland. (Yang Decl. ¶ 3–4; Def. Br. p. 2.) Yang has never resided in, held a driver’s license from, owned property in, or otherwise lived in New Jersey. (Yang Decl. ¶ 5.) In or around June 2019, Ascentage used a global recruiting firm to recruit Tripp for employment. (Tripp Decl. ¶ 1.) At the time, Tripp was living in New Jersey. (Id.) The recruiting firm organized an in-person meeting between Tripp and Yang in Chicago, Illinois. (Id. at ¶ 2.) Following the conference, Tripp, now back in New Jersey, continued to negotiate the terms and conditions of his employment with Ascentage via telephone. (Id. at ¶ 3.) In August 2019, Tripp began working for Ascentage in the position of “SVP, Portfolio Management and US Operations.” (Compl. ¶ 13.) Throughout his employment with Ascentage, Tripp worked full-time at his home in New Jersey. (Tripp Decl. ¶ 4.) Tripp paid New Jersey income, disability, and unemployment tax on his wages from Ascentage. (Id. at ¶ 5.) Ascentage also “utilized [Tripp’s] physical location in New Jersey so that [he] could contact potential investors located in the area, particularly New York City, which is approximately 20 minutes from [his] home.” (Id. at ¶ 6.) Additionally, Tripp occasionally “met in-person with other Ascentage employees in New Jersey, including at an Ascentage office that was located at 100 Connell Drive, Berkeley Heights, New Jersey. That office was closed in or around March 2021.” (Id. at ¶ 7; Pl. Br. p. 3.) At least 14 other Ascentage employees work remotely from their homes in New Jersey. (Compl. ¶ 9; Cheng Decl. ¶ 10; see also Pl. Br. p. 4 n.2.) In order to facilitate Tripp’s remote work, Ascentage provided him with a company-issued laptop, cell phone, and printer/scanner. (Tripp Decl. ¶ 8.) While working remotely in New Jersey, Tripp sent or received more than 50 work emails per day, made or received approximately 5 work phone calls per day, and participated in Microsoft Teams video conferences about 3 or 4 times per day. (Id. at ¶ 10.) Tripp also stored “highly confidential company information and documents” at his home office. (Id. at ¶ 9.) Yang supervised Tripp’s work and made decisions regarding his compensation and annual bonuses. (Compl. ¶ 14; Tripp Decl. ¶ 15.) During his employment with Ascentage, Tripp never received a warning that his employment with the company could be in jeopardy, and, in January 2022, Tripp received 99% of his 2021 targeted bonus. (Compl. ¶¶ 16–17.) On February 21, 2022, Tripp was rushed to the emergency room with “extreme pain in his abdomen due to a bowel obstruction.” (Compl. ¶ 18.) Tripp was admitted to the hospital and stayed overnight. (Id.) Tripp advised Ascentage of his hospitalization the next day and was released from the hospital on February 25, 2022. (Id. at ¶¶ 19, 21.) Also on February 25, Tripp contacted Jason Gilmore, Ascentage’s director of human resources, and informed him that he would need to take medical leave. (Id. at ¶ 26.) Gilmore advised Tripp to apply for short-term disability benefits in New Jersey and also under Ascentage’s private disability plan, New York Life. Both of those applications were approved. (Compl. ¶ 27; Tripp Decl. ¶ 11.) Gilmore advised Tripp that he would update Yang on Tripp’s medical condition. (Compl. ¶ 28.) At the direction of his gastroenterologist, Tripp took a short-term disability leave from work so that more tests could be conducted and he could recover. (Id. at ¶ 24.) On March 23, 2022, Tripp advised Gilmore that he hoped to return from leave on April 18, 2022. (Id. at ¶ 31.) On April 18, 2022, Tripp met with Gilmore and Jeff Kmetz, who is Ascentage’s chief business officer. (Compl. ¶ 34; Tripp Decl. ¶ 13.) They met via video conference, with Tripp in New Jersey, Kmetz in California, and Gilmore in Maryland. (Tripp Decl. ¶ 13.) During the meeting, Kmetz stated to Tripp, “we know today is your first day back, but we are letting you go.” (Compl. ¶ 36.) Kmetz did not provide any reason for the termination and advised Tripp that the termination decision was made by Yang. (Compl. ¶ 37; Tripp Decl. ¶ 13.) Gilmore emailed Tripp a proposed separation and release agreement offering two weeks of severance and one month of COBRA in return for Tripp’s agreeing to release all legal claims against Ascentage. Tripp did not sign the agreement. (Compl. ¶ 39; Tripp Decl. ¶ 14.) After his termination, Tripp applied for and received unemployment benefits from New Jersey. (Tripp Decl. ¶ 16.) On October 7, 2022, Tripp filed this action. The complaint asserts six claims: disability discrimination under the New Jersey Law Against Discrimination (“NJLAD”) (Counts 1 and 2); unlawful retaliation under NJLAD (Count 3); unlawful interference under the Family and Medical Leave Act (“FMLA”) (Count 4); failure to restore under FMLA (Count 5); and unlawful retaliation under FMLA (Count 6). (DE 1.) On December 6, 2022, defendants Ascentage and Yang filed a motion to dismiss.2 (DE 4.) Tripp filed an opposition, to which defendants replied. (DE 5, 6.) II. RULE 12(B)(2) STANDARD A plaintiff bears the burden of establishing sufficient facts to show that personal jurisdiction exists. Marten v. Godwin, 499 F.3d 290, 295–96 (3d Cir. 2001). While a court must accept the plaintiff’s allegations as true and construe disputed facts in favor of the plaintiff, Pinker v. Roche Holdings, Ltd., 292 F.3d 361, 368 (3d Cir. 2002), it must still examine any evidence presented with regard to disputed factual allegations, see, e.g., Eurofins Pharma US Holdings v. BioAlliance Pharma SA, 623 F.3d 147, 155–56 (3d Cir. 2010) (examining the evidence supporting the plaintiff’s allegations); Patterson v. FBI, 893 F.2d 595, 603–04 (3d Cir.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

International Shoe Co. v. Washington
326 U.S. 310 (Supreme Court, 1945)
World-Wide Volkswagen Corp. v. Woodson
444 U.S. 286 (Supreme Court, 1980)
Calder v. Jones
465 U.S. 783 (Supreme Court, 1984)
Helicopteros Nacionales De Colombia, S. A. v. Hall
466 U.S. 408 (Supreme Court, 1984)
Imo Industries, Inc. v. Kiekert Ag
155 F.3d 254 (Third Circuit, 1998)
Marten v. Godwin
499 F.3d 290 (Third Circuit, 2007)
O'CONNOR v. Sandy Lane Hotel Co., Ltd.
496 F.3d 312 (Third Circuit, 2007)
AMERIPAY, LLC v. Ameripay Payroll, Ltd.
334 F. Supp. 2d 629 (D. New Jersey, 2004)
Walden v. Fiore
134 S. Ct. 1115 (Supreme Court, 2014)
Miller Yacht Sales, Inc. v. Smith
384 F.3d 93 (Third Circuit, 2004)
Roberts Ex Rel. Roberts v. United States
710 F. App'x 512 (Third Circuit, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
TRIPP v. ASCENTAGE PHARMA GROUP INTERNATIONAL, Counsel Stack Legal Research, https://law.counselstack.com/opinion/tripp-v-ascentage-pharma-group-international-njd-2023.